Levin Capital Strategies’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Levin Capital Strategies’s Portfolio NVLN Stock Details NVLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-18,484	Closed	-$16K	–	269
2018 Q4	$16K	Sell	18,484 -32,211	-64%	-$36.4K	﹤0.01%	251
2018 Q3	$150K	Hold	50,695	–	–	﹤0.01%	251
2018 Q2	$187K	Hold	50,695	–	–	﹤0.01%	260
2018 Q1	$177K	Hold	50,695	–	–	﹤0.01%	279
2017 Q4	$158K	Sell	50,695 -107,181	-68%	-$515K	﹤0.01%	286
2017 Q3	$1.11M	Sell	157,876 -2,966	-2%	-$23.8K	0.02%	138
2017 Q2	$1.49M	Sell	160,842 -22,953	-12%	-$221K	0.03%	128
2017 Q1	$1.97M	Sell	183,795 -86,758	-32%	-$887K	0.04%	112
2016 Q4	$2.28M	Buy	+270,553	New	+$2.4M	0.04%	118

Other funds holding NVLN

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

HVC

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Levin Capital Strategies's NVLN Position: Q1 2019 in Review

Levin Capital Strategies sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q1 2019, closing a stake of 18,484 shares — an estimated $16K sold.

Levin Capital Strategies first reported a position in NVLN in Q4 2016 and held it in 9 quarters. The position peaked at $2.28M in Q4 2016. 35 funds tracked by Wall St. Rank hold NVLN as of Q1 2019.

Levin Capital Strategies reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q1 2019 after selling out during the quarter.
Levin Capital Strategies sold 18,484 Novelion Therapeutics Inc. Common Shares shares in Q1 2019, an estimated $16K.
Levin Capital Strategies first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 9 quarters.
Levin Capital Strategies's Novelion Therapeutics Inc. Common Shares position peaked at $2.28M in Q4 2016.
35 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q1 2019.

Based on Levin Capital Strategies's 13F filing for Q1 2019, filed 13 May 2019.